# US 9,517,217 B2 · Immune cell activation inhibitor and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,517,217 B2
- Document ID: US9517217B2
- Status: Granted
- Kind: B2
- Application number: 14/419,182
- Filed: 2013-08-02
- Published: 2015-07-23
- Granted: 2016-12-13
- Earliest claimed: 2012-08-03
- Assignees: Ehime University
- Applicants: Ehime University
- Inventors: Junya Tanaka
- Web page: https://patentgrep.com/patent/US9517217B2

## CPC

- A61K 31/17: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 17/08: Antiseborrheics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a pharmaceutical that can be used widely for intractable neurological diseases, inflammatory diseases, etc. The immune cell activation inhibitor of the present invention contains bromovalerylurea or a derivative thereof. The immune cell activation inhibitor of the present invention can be used as a pharmaceutical for, for example: chronic neurological diseases such as Parkinson's disease and Alzheimer's disease; acute neurological diseases such as cerebral infarction and brain injury; and inflammatory diseases such as systemic inflammatory response syndromes.

## Claims

### Claim 1

A method for treating an inflammatory disease, the method comprising a step of:
administering transdermally to a subject a pharmaceutical of treating an inflammatory disease in an effective amount thereof,
wherein an active ingredient exhibiting an anti-inflammatory activity in the pharmaceutical consists of: bromovalerylurea or a hydrate, solvate, isomer or a salt thereof, and
the pharmaceutical is in a form of ointment, cream, or lotion for the transdermal administration.

### Claim 2 (depends on 1)

The method for treating an inflammatory disease according to claim 1, wherein the inflammatory disease is an inflammatory skin disease.

### Claim 3 (depends on 2)

The method for treating an inflammatory disease according to claim 2,
wherein the inflammatory skin disease is at least one disease selected from the group consisting of atopic dermatitis, contact dermatitis, psoriasis, eczema, diaper dermatitis, seborrheic dermatitis, lichen simplex chronicus Vidal, autosensitization dermatitis, senile xerosis, actinic dermatitis, bullous diseases, keloid, erythroderma, drug eruption, and toxicoderma.